FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type (check only one) 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type (check only one) 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

  
gfedcb

If this is a report of a second or subsequent transplant, check here and continue with question 218.

 
 
1  What was the date of diagnosis of Neuroblastoma? __ __ __ __ - __ __- __ __  

 

Specify the site(s) of primary tumor(s) at diagnosis: 
 

2  Adrenal gland

    
 nmlkji

yes  
 nmlkji

no  

 
 
3  Number of tumors present    

 
 

4  Bone

    
 nmlkji

yes  
 nmlkji

no  

 
 
5  Number of tumors present    

 
 

6  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  

 
 
7  Number of tumors present    

 
 

8  Cerebellum

    
 nmlkji

yes  
 nmlkji

no  

 
 
9  Number of tumors present    

 
 

10  Cerebrospinal fluid (CSF)

    
 nmlkji

yes  
 nmlkji

no  

 
 
11  Number of tumors present    

 
 

12  Cerebrum

    
 nmlkji

yes  
 nmlkji

no  

 
 
13  Number of tumors present    

Key Fields 

  Clinical and Laboratory Characteristics at Diagnosis Questions: 1 - 61

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 15



 
 

14  Cranial nerves

    
 nmlkji

yes  
 nmlkji

no  

 
 
15  Number of tumors present    

 
 

16  Liver

    
 nmlkji

yes  
 nmlkji

no  

 
 
17  Number of tumors present    

 
 

18  Lymph nodes

    
 nmlkji

yes  
 nmlkji

no  

 
 
19  Number of tumors present    

 
 

20  Mediastinum

    
 nmlkji

yes  
 nmlkji

no  

 
 
21  Number of tumors present    

 
 

22  Paraspinal ganglion

    
 nmlkji

yes  
 nmlkji

no  

 
 
23  Number of tumors present    

 
 

24  Retro-orbital area

    
 nmlkji

yes  
 nmlkji

no  

 
 
25  Number of tumors present    

 
 

26  Skin / subcutaneous tissue

    
 nmlkji

yes  
 nmlkji

no  

 
 
27  Number of tumors present    

 
 

28  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
29  Number of tumors present    

 
 
30  Specify other site:    

 
 

31  Location of primary tumor(s) unknown

    
 nmlkji

yes  
 nmlkji

no  

 
 

32  Were metastases present at diagnosis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the site(s) of metastases: 
 

33  Adrenal gland

    
 nmlkji

yes  
 nmlkji

no  

 
 

34  Bone

    
 nmlkji

yes  
 nmlkji

no  

 
 

35  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  

 
 

36  Cerebellum

    
 nmlkji

yes  
 nmlkji

no  

 
 

37  Cerebrospinal fluid (CSF)

    
 nmlkji

yes  
 nmlkji

no  

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 15



 
 

38  Cerebrum

    
 nmlkji

yes  
 nmlkji

no  

 
 

39  Cranial nerves

    
 nmlkji

yes  
 nmlkji

no  

 
 

40  Liver

    
 nmlkji

yes  
 nmlkji

no  

 
 

41  Lymph nodes

    
 nmlkji

yes  
 nmlkji

no  

 
 

42  Mediastinum

    
 nmlkji

yes  
 nmlkji

no  

 
 

43  Paraspinal ganglion

    
 nmlkji

yes  
 nmlkji

no  

 
 

44  Retro-orbital area

    
 nmlkji

yes  
 nmlkji

no  

 
 

45  Skin / subcutaneous tissue

    
 nmlkji

yes  
 nmlkji

no  

 
 

46  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
47  Specify other site:    

 

Specify any radiographic tests used to evaluate the disease status at diagnosis: 
 

48  CT scan

    
 nmlkji

yes  
 nmlkji

no  

 
 

49  Magnetic resonance imaging (MRI)

    
 nmlkji

yes  
 nmlkji

no  

 
 

50  I-meta-iodobenzylguanidine scan (MIBG)

    
 nmlkji

yes  
 nmlkji

no  

 
 

51  Skeletal survey

    
 nmlkji

yes  
 nmlkji

no  

 
 

52  Technetium scan

    
 nmlkji

yes  
 nmlkji

no  

 
 

53  Were any biopsies performed at diagnosis?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the biospy site(s) postivie for neuroblastoma: 
 

54  Bone Marrow

    
 nmlkji

yes  
 nmlkji

no  

 
 

55  Primary tumor

    
 nmlkji

yes  
 nmlkji

no  

 
 

56  Skin

    
 nmlkji

yes  
 nmlkji

no  

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 15



 
 

57  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
58  Specify other site:    

 
 

59  Specify the histologic findings by Shimada classification:

    
 nmlkji

stroma-rich  

 nmlkji
stroma-poor  

 nmlkji
not classified / unknown  

 
 

60  Specify histology:

    
 nmlkji

nodular  

 nmlkji
well differentiated / intermixed  

 
 

61  Specify histology:

    
 nmlkji

favorable  
 nmlkji

unfavorable  

 
 

62  WBC:

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
63     

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

64  Hemoglobin (untransfused):

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
65     

 

 nmlkji
g/dL  

 nmlkji
g/L  

 nmlkji
mmol/L  

 
 

66  Platelets (untransfused):

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
67     

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

68  Hematocrit:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
69     % 

 

Specify the following tumor marker analyses performed at diagnosis: 
 

70  Homovanillic acid (HVA):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
71     

µg/mg creatinine 

 
 

72  Neuron specific enolase:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
73     ng/mL 

 
 

74  Serum ferritin:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
75     ng/mg or µg/L 

  Laboratory Values at Diagnosis of Neuroblastoma Questions: 62 - 232

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 15



 
 

76  Vanilmandelic acid (VMA):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
77     

µg/mg creatinine 

 
 

78  LDH:

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
79     

 

 nmlkji
U/L  

 nmlkji
µkat/L  

 
 
80  Upper limit of normal for LDH:    

 
 

81  Other tumor marker analysis:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
82  Specify other analysis:    

 
 
83  Specify level and units:    

 
 

84  Was a DNA analysis performed at diagnosis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the tissue(s) analyzed: 
 

85  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  

 
 

86  First degree tumor

    
 nmlkji

yes  
 nmlkji

no  

 
 

87  Other tissue

    
 nmlkji

yes  
 nmlkji

no  

 
 
88  Specify other tissue:    

 

Specify ploidy: 
 

89  Modal number:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
90     

 
 

91  DNA index:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
92     

 

Specify any methods used to determine the presense of proto-oncogenes: 
 

93  N-myc amplification:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 

94  Were proto-oncogenes detected?

    
 nmlkji

yes  
 nmlkji

no  

 
 
95  Specify copy number:    

 
 

96  trk A expression:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 

97  Specify expression of proto-oncogenes:

    
 nmlkji

high  
 nmlkji

low  
 nmlkji

Absent  

 
 

98  Were any other molecular abnormalities present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 15



 
 
99  Specify other molecular abnormality:    

 
 

100  Is a copy of the DNA report attached?

    
 nmlkji

yes  
 nmlkji

no  

 
 

101  Was a cytogenetic analysis performed at diagnosis?

    
 nmlkji

Yes  

 nmlkji
yes, but no 

evaluable 
metaphases  

 nmlkji
No  

 nmlkji
Unknown  

 

Specify the tissue(s) analyzed: 
 

102  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  

 
 

103  First degree tumor

    
 nmlkji

yes  
 nmlkji

no  

 
 

104  Other tissue

    
 nmlkji

yes  
 nmlkji

no  

 
 
105  Specify other tissue:    

 
 

106  Number of metaphases:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
107     

 
 

108  Was the karyotype abnormal?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the karyotype abnormalities: 
 

109  1p-

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

110  14q-

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

111  17q+

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

112  +17

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

113  Other abnormality

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
114  Specify:    

 
 

115  Is a copy of the cytogenetic report attached?

    
 nmlkji

yes  
 nmlkji

no  

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 15



 
116  Specify the International Neuroblastoma Staging System (INSS) disease stage at diagnosis:

    
 nmlkji

Stage 1 - localized tumor with complete gross excision, with or without microscopic residual disease; representative ipsilateral lymph nodes negative for tumor 
microscopically (nodes attached to and removed with the primary tumor may be positive)  

 nmlkji
Stage 2A - localized tumor with incomplete gross excision; representative ipsilateral nonadherent lymph nodes negative for tumor microscopically  

 nmlkji
Stage 2B - localized tumor with or without complete gross excision, with ipsilateral nonadherent lymph nodes positive for tumor; enlarged contralateral lymph nodes must be 

negative microscopically  

 nmlkji
Stage 3 - unresectable unilateral tumor infiltrating across the midline (defined as the vertebral column; tumors originating on one side and crossing the midline must 

infiltrate to or beyond the opposite side of the vertebral column), with or without regional lymph node involvement; or localized unilateral tumor with contralateral regional 
lymph node involvement; or midline tumor with bilateral extension by infiltration (unresectable) or by lymph node involvement  

 nmlkji
Stage 4 - any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin and/or other organs (except as defined for Stage 4S)  

 nmlkji
Stage 4S - localized primary tumor (as defined for Stages 1, 2A, or 2B), with dissemination limited to skin, liver, and/or bone marrow (marrow involvement in Stage 4S should 

be minimal; i.e., < 10% of total nucleated cells identified as malignant on bone marrow biopsy or on marrow aspirate; more extensive marrow involvement would be 
considered to be Stage 4; the MIBG scan (if performed) should be negative in the marrow). Stage 4S is limited to infants < 1 year of age.  

 nmlkji
Unknown  

If the INSS cannot be determined, then the Pediactric Oncology Group (POG) Staging System - or - The Evans Group Statging System may be reported: 
 

117  Specify the POG Stage:

    
 nmlkji

A - complete gross excision of primary tumor, margins histologically negative or positive. Intracavitary lymph nodes not intimately adhered to and removed with 
resected tumor must be histologically free of tumor. If primary is in abdomen or pelvis, liver must be histologically free of tumor.  

 nmlkji
B - incomplete gross resection of primary. Lymph nodes and liver must be histologically free of tumor.  

 nmlkji
C - complete or incomplete gross resection of primary. Intracavitary nodes (cavity of primary) histologically positive for tumor. Liver histologically free of tumor.  

 nmlkji
D - disseminated disease beyond intracavitary nodes in bone marrow, bone, liver, skin or lymph nodes beyond cavity containing primary tumor.  

 nmlkji
Unknown  

 
118  Specify the Evans Stage:

    
 nmlkji

I - tumor confined to the organ structure of origin  

 nmlkji
II - tumors extending in continuity beyond the organ or structure of origin but not crossing the midline. Regional lymph nodes on the homolateral side may be 

involved.  

 nmlkji
III - tumors extending in continuity beyond the organ or structure of origin but not crossing the midline. Regional lymph nodes on the homolateral side may be 

involved.  

 nmlkji
IV - remote disease involving skeleton, soft tissues, distant lymph node groups, etc.  

 nmlkji
IV-S - patients with local stage I or II disease but who have remote disease confined to one or more of the following: liver, skin, bone marrow, (with no evidence of 

bone metastases on complete skeletal survey)  

 nmlkji
Unknown  

 
 

119  Are other family members known to have neuroblastoma or ganglioneuroma?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the family member(s) diagnosed with neuroblastoma or ganglioneuroma: 
 

120  Father

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

121  Mother

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

122  Sister

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
123  Specify the number of sisters affected:    

 
  

gfedcb
Number of affected sisters unknown

 
 

124  Brother

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 15



  
 
125  Specify the number of brothers affected:    

 
  

gfedcb
Number of affected brothers unknown

 
 

126  Other relative

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
127  Specify relationship:    

 
 

128  Does the recipient have a family history of other genetic diseases in first-degree blood relatives?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the diagnoses present in the immediate family: 
 

129  Beckwith-Wiedemann syndrome (EMG syndrome)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

130  Nesidioblastosis

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

131  Neurofibromatosis

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

132  Trisomy 18

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

133  Other disease

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
134  Specify genetic disease:    

 
 

135  Did spontaneous regression of the recipient's tumor occur?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

136  Did the recipient undergo surgery as part of the initial disease treatment plan?

    
 nmlkji

yes  
 nmlkji

no  

 
 

137  Specify surgery timepoint:

    
 nmlkji

at diagnosis  

 nmlkji
after induction chemotherapy  

 nmlkji
Unknown  

 
 

138  Specify the histological diagnosis of resected tissue:

    
 nmlkji

ganglioneuroblastoma  
 nmlkji

ganglioneuroma  
 nmlkji

neuroblastoma  

 

Specify the site(s) of surgery: 
 

139  Abdomen

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

140  Extent of surgery:

    
 nmlkji

Gross  
 nmlkji

Near  
 nmlkji

Subtotal  
 nmlkji

Partial  
 nmlkji

Biopsy  

 
 
141  Date of surgery: __ __ __ __ - __ __- __ __  

 
 

142  Head or neck

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 15



 
 

143  Extent of surgery:

    
 nmlkji

Gross  ->95% resection, no radiographic residual tumor 

 nmlkji
Near  -90-95% resection, minimal radiographic residual tumor 

 nmlkji
Subtotal  -51-89% resection, moderate radiographic residual tumor 

 nmlkji
Partial  -10-50% resection, significant radiographic residual tumor 

 nmlkji
Biopsy  -<10% resection, no radiographic change post-op from pre-op 

 
 
144  Date of surgery: __ __ __ __ - __ __- __ __  

 
 

145  Mediastinum

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

146  Extent of surgery:

    
 nmlkji

Gross  
 nmlkji

Near  
 nmlkji

Subtotal  
 nmlkji

Partial  
 nmlkji

Biopsy  

 
 
147  Date of surgery: __ __ __ __ - __ __- __ __  

 
 

148  Pelvis

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

149  Extent of surgery:

    
 nmlkji

Gross  
 nmlkji

Near  
 nmlkji

Subtotal  
 nmlkji

Partial  
 nmlkji

Biopsy  

 
 
150  Date of surgery: __ __ __ __ - __ __- __ __  

 
 

151  Other site:

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

152  Extent of surgery:

    
 nmlkji

Gross  
 nmlkji

Near  
 nmlkji

Subtotal  
 nmlkji

Partial  
 nmlkji

Biopsy  

 
 
153  Date of surgery: __ __ __ __ - __ __- __ __  

 
 
154  Specify other surgery site:    

 
 

155  Did the recipient undergo radiotherapy as part of the initial disease treatment plan?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the site(s) of radiotherapy: 
 

156  Primary tumor bed after resection

    
 nmlkji

yes  
 nmlkji

no  

 
 
157  Specify total number of fractions given:    

 
 
158  Specify the dose per fraction:    cGy (rads) 

 
 

159  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
160  Specify other radiotherapy site:    

 
 
161  Specify total number of fractions given:    

 
 
162  Specify the dose per fraction:    cGy (rads) 

 
 

163  Did the recipient undergo chemotherapy as part of the initial disease treatment plan?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
164  Specify the date the first chemotherapy cycle began: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date the first chemotherapy cycle began unknown

  
 
165  Specify the date the last chemotherapy cycle began: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date the last chemotherapy cycle began unknown

  
 
166  Specify the total number of chemotherapy cycles given:    

 
  

gfedcb
Number of chemotherapy cycles given unknown

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 15



 

Specify the treatment(s) given: 
 

167  Adriamycin

    
 nmlkji

yes  
 nmlkji

no  

 
 

168  Cisplatin

    
 nmlkji

yes  
 nmlkji

no  

 
 

169  Cyclophosphamide

    
 nmlkji

yes  
 nmlkji

no  

 
 

170  Dacarbazine (DTIC)

    
 nmlkji

yes  
 nmlkji

no  

 
 

171  Etoposide (VP16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

172  Ifosfamide

    
 nmlkji

yes  
 nmlkji

no  

 
 

173  Melphalan (L-PAM)

    
 nmlkji

yes  
 nmlkji

no  

 
 

174  Retinoids

    
 nmlkji

yes  
 nmlkji

no  

 
 

175  Teniposide (VM26)

    
 nmlkji

yes  
 nmlkji

no  

 
 

176  Vincristine

    
 nmlkji

yes  
 nmlkji

no  

 
 

177  Other treatment

    
 nmlkji

yes  
 nmlkji

no  

 
 
178  Specify treatment:    

 
179  Specify the best response to chemotherapy:

    (Internationl Neuroblastoma Response Criteria)  

 nmlkji
complete response (CR) - no primary tumor, no metastatic sites, catecholamines normal  

 nmlkji
very good partial response (VGPR) - primary tumor decreased by 90-99%, no metastatic sites, catecholamines normal; residual 99Tc bone changes allowed  

 nmlkji
partial response (PR) - primary tumor decreased by > 50%, all measurable metastatic sites decreased by > 50%, number of positive bone sites decreased by > 50%, 

no more than 1 positive bone marrow site allowed, 1 positve marrow aspirate or biopsy allowed if this represents a decrease from the number of postive sites at 
diagnosis  

 nmlkji
minimal response (MR) - no new lesions; > 50% reduction of any measurable lesion (primary or metastases) with < 50% reduction in any other; < 25% increase in 

any existing lesion  

 nmlkji
no response (NR) - no new lesions; < 50% reduction but < 25% increase in any existing lesion  

 nmlkji
progressive disease (PD) - any new lesions; increase of any measurable lesion by > 25%; previous negative marrow positive for tumor  

 nmlkji
not evaluable (NE)  

 nmlkji
not tested / unknown  

 
 

180  Did neuroblastoma recur?

    
 nmlkji

yes  
 nmlkji

no  

 
 
181  Specify the date of recurrence: __ __ __ __ - __ __- __ __  

 
 
182  Specify reason:    

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 10 / 15



  
 
183  Specify the date of the best response to chemotherapy was determined __ __ __ __ - __ __- __ __  

 

  

gfedcb
Date best response to chemotherapy was determined 
unknown 

 
 

184  Did the recipient undergo surgery, chemotherapy or other cytotoxic treatment for persistent or recurrent disease after the initial treatment but prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  

 
 
185  Date therapy started: __ __ __ __ - __ __- __ __  

 
 
186  Date therapy stopped: __ __ __ __ - __ __- __ __  

 
 

187  Systemic Therapy:

    
 nmlkji

yes  
 nmlkji

no  

  
 
188  Number of cycles    

 
  

gfedcb
Number of cycles unknown/not applicable

 

Treatment: 
 

189  Adriamycin:

    
 nmlkji

yes  
 nmlkji

no  

 
 

190  Cisplatin:

    
 nmlkji

yes  
 nmlkji

no  

 
 

191  Cyclophosphamide:

    
 nmlkji

yes  
 nmlkji

no  

 
 

192  Dacarbazine (DTIC):

    
 nmlkji

yes  
 nmlkji

no  

 
 

193  Etoposide (VP-16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

194  Ifosfamide (IFEX):

    
 nmlkji

yes  
 nmlkji

no  

 
 

195  Melphalan (L-PAM):

    
 nmlkji

yes  
 nmlkji

no  

 
 

196  Retinoids:

    
 nmlkji

yes  
 nmlkji

no  

 
 

197  Teniposide (VM26):

    
 nmlkji

yes  
 nmlkji

no  

 
 

198  Vincristine:

    
 nmlkji

yes  
 nmlkji

no  

 
 

199  Other therapy:

    
 nmlkji

yes  
 nmlkji

no  

 
 
200  Specify other therapy    

 
 

201  Radiation Therapy:

    
 nmlkji

yes  
 nmlkji

no  

 
 

202  Primary tumor bed:

    
 nmlkji

yes  
 nmlkji

no  

 
 
203  Specify number of fractions:    cGy (rads) 

 
 
204  Specify dose / fraction:    cGy (rads) 

  Line of Therapy (1) Questions: 185 - 217 

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 11 / 15



 
 

205  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
206  Specify other site:    

 
 
207  Specify number of fractions:    cGy (rads) 

 
 
208  Specify dose / fraction:    cGy (rads) 

 
 

209  Surgical Biopsy/Resection:

    
 nmlkji

yes  
 nmlkji

no  

 
 
210  Specify site:    

 
 

211  Type of surgery:

    
 nmlkji

gross total  
 nmlkji

near total  
 nmlkji

subtotal  
 nmlkji

partial  
 nmlkji

biopsy  

 
 

212  Histologic diagnosis:

    
 nmlkji

neuroblastoma  
 nmlkji

ganglioneuroblastoma  
 nmlkji

ganglioneuroma  

 
213  Best response to line of therapy:

    
 nmlkji

CR  -Complete response-no primary tumor, no metastatic sites, catecholamines normal 

 nmlkji
VGPR  -Very good partial response-primary tumor decreased by 90-99%, no metastatic sites catecholamines normal; residual 99Tc bone changes allowed 

 nmlkji
PR  -Partial response-primary tumor decreased by 50%, all measurable metastatic sites decreased by >50%, number of positive bone sites decreased by 

>50%, no more than 1 positive bone marrow site allowed, 1 positive marrow aspirate or biopsy allowed if this represents a decrease from the number of 

positive sites at diagnosis  

 nmlkji
MR  -Minimal response-no new lesions; >50% reduction of any measurable lesion (primary or metastases) with <50% reduction in any other; <25% increase in 

any existing lesion  

 nmlkji
NR  -No response-no new lesions; <50% reduction but <25% increase in any existing lesion 

 nmlkji
PD  -Progressive disease-any new lesions; increase of any measurable lesion by >25%; previous negative marrow positive for tumor 

 nmlkji
NE  -Not evaluable 

 nmlkji
Unk  -Unknown 

 
 
214  Specify reason:    

 
 
215  Date response evaluated: __ __ __ __ - __ __- __ __  

 
 

216  Did the patient relapse/progress
following this line of therapy? 

    
 nmlkji

yes  
 nmlkji

no  

 
 
217  Date of relapse/progression: __ __ __ __ - __ __- __ __  

 

Specify any sites of tumor involvement at any time after diagnosis but prior to the preparative regimen: (For subsequent HSCT reports, list sites between last HSCT and the 

preparative regimen for subsequent HSCT.)  
 

218  Adrenal gland

    
 nmlkji

yes  
 nmlkji

no  

 
 

219  Bone

    
 nmlkji

yes  
 nmlkji

no  

 
 

220  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  

 
 

221  Cerebellum

    
 nmlkji

yes  
 nmlkji

no  

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 12 / 15



 
 

222  Cerebrospinal fluid (CSF)

    
 nmlkji

yes  
 nmlkji

no  

 
 

223  Cerebrum

    
 nmlkji

yes  
 nmlkji

no  

 
 

224  Cranial nerves

    
 nmlkji

yes  
 nmlkji

no  

 
 

225  Liver

    
 nmlkji

yes  
 nmlkji

no  

 
 

226  Lymph nodes

    
 nmlkji

yes  
 nmlkji

no  

 
 

227  Mediastinum

    
 nmlkji

yes  
 nmlkji

no  

 
 

228  Paraspinal ganglion

    
 nmlkji

yes  
 nmlkji

no  

 
 

229  Retro-orbital area

    
 nmlkji

yes  
 nmlkji

no  

 
 

230  Skin / subcutaneous tissue

    
 nmlkji

yes  
 nmlkji

no  

 
 

231  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
232  Specify other site:    

 
 

233  Were tumor marker analyses performed immediately prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the following tumor marker analyses performed: 
 

234  Homovanillic acid (HVA):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
235     µg/mg creatinine 

 
 
236  Date of analysis: __ __ __ __ - __ __- __ __  

 
 

237  Neuron specific enolase:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
238     ng/mL 

 
 
239  Date of analysis: __ __ __ __ - __ __- __ __  

 
 

240  Serum ferritin:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
241     ng/mg or µg/L 

 
 
242  Date of analysis: __ __ __ __ - __ __- __ __  

 
 

243  Vanilmandelic acid (VMA):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
244     µg/mg creatinine 

 
 
245  Date of analysis: __ __ __ __ - __ __- __ __  

  Disease Status Immediately Prior to Preparative Regiman Questions: 233 - 271

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 13 / 15



 
 

246  Other tumor marker analysis:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
247  Specify other analysis:    

 
 
248  Specify level and units:    

 
249  Specify the disease status immediately prior to the preparative regimen:

    
 nmlkji

complete response (CR) - no primary tumor, no metastatic sites, catecholamines normal  

 nmlkji
very good partial response (VGPR) - primary tumor decreased by 90-99%, no metastatic sites, catecholamines normal; residual 99Tc bone changes allowed  

 nmlkji
partial response (PR) - primary tumor decreased by > 50%, all measurable metastatic sites decreased by > 50%, number of positive bone sites decreased by > 50%, no 

more than 1 positive bone marrow site allowed, 1 positve marrow aspirate or biopsy allowed if this represents a decrease from the number of postive sites at diagnosis  

 nmlkji
minimal response (MR) - no new lesions; > 50% reduction of any measurable lesion (primary or metastases) with < 50% reduction in any other; < 25% increase in any 

existing lesion  

 nmlkji
no response (NR) - no new lesions; < 50% reduction but < 25% increase in any existing lesion  

 nmlkji
progressive disease (PD) - any new lesions; increase of any measurable lesion by > 25%; previous negative marrow positive for tumor  

 nmlkji
not evaluable (NE)  

 nmlkji
not tested / unknown  

 
 
250  Specify the total number of complete remissions:    

 

Specify any known sites of disease immediately prior to the preparative regimen: 
 

251  Adrenal gland

    
 nmlkji

yes  
 nmlkji

no  

 
 

252  Bone

    
 nmlkji

yes  
 nmlkji

no  

 
 

253  Bone Marrow

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the method(s) used to evaluate the disease status immediately prior to the preparative regimen: 
 

254  Bone marrow morphology

    
 nmlkji

yes  
 nmlkji

no  

 
 

255  Flow cytometric analysis

    
 nmlkji

yes  
 nmlkji

no  

 
 

256  Immunofluorescence

    
 nmlkji

yes  
 nmlkji

no  

 
 

257  Cerebellum

    
 nmlkji

yes  
 nmlkji

no  

 
 

258  Cerebrospinal fluid (CSF)

    
 nmlkji

yes  
 nmlkji

no  

 
 

259  Cerebrum

    
 nmlkji

yes  
 nmlkji

no  

 
 

260  Cranial nerves

    
 nmlkji

yes  
 nmlkji

no  

 
 

261  Liver

    
 nmlkji

yes  
 nmlkji

no  

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 14 / 15



 
 

262  Lymph nodes

    
 nmlkji

yes  
 nmlkji

no  

 
 

263  Mediastinum

    
 nmlkji

yes  
 nmlkji

no  

 
 

264  Paraspinal ganglion

    
 nmlkji

yes  
 nmlkji

no  

 
 

265  Retro-orbital area

    
 nmlkji

yes  
 nmlkji

no  

 
 

266  Skin / subcutaneous tissue

    
 nmlkji

yes  
 nmlkji

no  

 
 

267  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
268  Specify other site:    

 
 
269  Specify the percent of cells positive for neuroblastoma:    % 

 
 
270  Specify reason:    

 
 
271  Specify the date the disease status was determined: __ __ __ __ - __ __- __ __  

  
 
First Name:    

 
Last Name:    

  
 
Phone:    

 
Fax number:    

 
 
E-mail address:    

Form 2026 R2.0: Neuroblastoma Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2026 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 15 / 15